Modality
siRNA
MOA
C5i
Target
CGRP
Pathway
T-cell
CeliacPBCCrohn's
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
~Feb 2021
→ ~May 2022
Phase 3
~Aug 2022
→ ~Nov 2023
NDA/BLA
Feb 2024
→ Oct 2031
NDA/BLACurrent
NCT06429143
1,038 pts·PBC
2024-02→2031-10·Not yet recruiting
1,038 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-025.5y awayPh3 Readout· PBC
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2031-10-02 · 5.5y away
PBC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06429143 | NDA/BLA | PBC | Not yet recr... | 1038 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 |